Literature DB >> 11135435

A search for germline APC mutations in early onset colorectal cancer or familial colorectal cancer with normal DNA mismatch repair.

L A Boardman1, S Schmidt, N M Lindor, L J Burgart, J M Cunningham, T Price-Troska, K Snow, D A Ahlquist, S N Thibodeau.   

Abstract

Twenty percent of colorectal cancers (CRCs) arise in people who have a family history of CRC in at least one other relative. Although a fraction of these CRCs are explained by two well-described autosomal dominant syndromes-5% by hereditary nonpolyposis colorectal cancer (HNPCC) and 1% by familial adenomatous polyposis (FAP)-the cause of the remaining 14% of familial aggregates of CRC is unknown. Many cases of HNPCC are due to germline mutations in DNA mismatch repair genes, leading to the tumor phenotype of microsatellite instability (MSI), and most cases of FAP are caused by germline APC mutations. To date, non-FAP familial CRC aggregates have not been evaluated for germline APC mutations. In this study, we examined the involvement of germline APC mutations in 79 individuals with CRC who had early-age onset of their cancer (age < 50 years) and/or a family history of CRC. Cases with FAP or HNPCC due to defective mismatch repair were excluded from the study. Using conformation-sensitive gel electrophoresis and the protein truncation test as the screening methods, no functionally significant germline mutations were detected for any of the cases. An apparently silent polymorphism resulting in a 1-bp alteration of A --> G (proline --> proline) in exon 4 was observed. Additionally, four intervening sequence (IVS) alterations were detected: IVS2-53t-->c in 3 cases; IVS4-17ins T in 3 cases; IVS5+32t-->c in 16 cases; and IVS5+33g-->a in 1 case. All appeared to be polymorphisms present in similar proportions in an average-risk population. We conclude that germline APC mutations do not account for familial MSS (stable microsatellite) CRC associated with few synchronous polyps. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11135435

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  6 in total

1.  Congenital hypertrophy of the retinal pigment epithelium (CHRPE) in familial colorectal cancer.

Authors:  Celia S Chen; Kerry D Phillips; Scott Grist; Graeme Bennet; Jamie E Craig; James S Muecke; Graeme K Suthers
Journal:  Fam Cancer       Date:  2006-08-31       Impact factor: 2.375

2.  Association of familial colorectal cancer with variants in the E-cadherin (CDH1) and cyclin D1 (CCND1) genes.

Authors:  Frank Grünhage; Matthias Jungck; Christoph Lamberti; Christine Berg; Ursula Becker; Hildegard Schulte-Witte; Dominik Plassmann; Nils Rahner; Stefan Aretz; Nicolaus Friedrichs; Reinhard Buettner; Tilman Sauerbruch; Frank Lammert
Journal:  Int J Colorectal Dis       Date:  2007-10-25       Impact factor: 2.571

3.  Missense polymorphisms in the adenomatous polyposis coli gene and colorectal cancer risk.

Authors:  Sean P Cleary; Hyeja Kim; Marina E Croitoru; Mark Redston; Julia A Knight; Steven Gallinger; Robert Gryfe
Journal:  Dis Colon Rectum       Date:  2008-07-10       Impact factor: 4.585

Review 4.  Early-onset colorectal cancer: initial clues and current views.

Authors:  Lorne J Hofseth; James R Hebert; Anindya Chanda; Hexin Chen; Bryan L Love; Maria M Pena; E Angela Murphy; Mathew Sajish; Amit Sheth; Phillip J Buckhaults; Franklin G Berger
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-02-21       Impact factor: 46.802

5.  Colorectal cancer in the course of familial adenomatous polyposis syndrome ("de novo" pathogenic mutation of APC gene): case report, review of the literature and genetic commentary.

Authors:  Rafał Stec; Andrzej Pławski; Agnieszka Synowiec; Michał Mączewski; Cezary Szczylik
Journal:  Arch Med Sci       Date:  2010-04-30       Impact factor: 3.318

6.  Genetic analysis of the APC gene regions involved in attenuated APC phenotype in Israeli patients with early onset and familial colorectal cancer.

Authors:  A Figer; L Irmin; R Geva; D Flex; A Sulkes; E Friedman
Journal:  Br J Cancer       Date:  2001-08-17       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.